Cryoport (CYRX) Q4 2025: Commercial Cell & Gene Therapy Revenue Surges 29%, Anchoring Long-Term Growth
Cryoport’s commercial cell and gene therapy revenue expanded rapidly, now representing a fifth of total sales and fueling a spring-loaded pipeline for future growth. The company’s shift toward high-value clinical and commercial therapy support, combined with operational discipline and strategic partnerships, positions it as a leading platform in the life sciences supply chain. With robust trial activity and key margin milestones in sight, execution on new therapy launches and integration of global alliances will dictate the pace of further gains.
Summary
- Commercial Therapy Momentum: Cell and gene therapy revenue now drives a larger share of the business and is set to outpace legacy segments.
- Operational Leverage Building: Cost initiatives and scale in bioservices are improving margin trajectory and EBITDA visibility.
- Strategic Partnerships Expanding: DHL, Cardinal Health, and Parexel alliances are extending Cryoport’s global reach and ecosystem depth.
Performance Analysis
Cryoport’s core business model, temperature-controlled supply chain solutions for life sciences, is increasingly anchored by commercial cell and gene therapy, which grew 29% year-over-year and now comprises 20% of total revenue. This shift is material, as it signals a transition from a clinical trial-heavy revenue mix toward durable, higher-value commercial support. The company supported a record 760 clinical trials and 20 commercial therapies globally, with clinical trial revenue also rising 14% year-over-year. The bioservices segment, which includes biostorage and related services, posted 22% growth, underscoring Cryoport’s ability to capture more revenue per client as therapies progress through the pipeline.
Gross margin improved to 47%, reflecting both operational discipline and scale. Adjusted EBITDA improved by $12 million year-over-year, and management reiterated the goal of achieving positive adjusted EBITDA in the second half of 2026. The MVE Biological Solutions segment, which manufactures cryogenic systems, grew 7% for the year, but its share of the business is expected to decline as commercial cell and gene therapy activity accelerates. Strategic investments in new facilities and digital transformation, including AI-driven workflow enhancements, are supporting both growth and efficiency.
- Commercial Revenue Inflection: The rapid expansion of commercial therapy support is structurally raising Cryoport’s growth baseline.
- Margin Expansion: Cost discipline and bioservices leverage are translating into improved profitability metrics.
- Segment Realignment: Legacy product growth remains steady, but future revenue mix will be increasingly weighted to higher-margin services.
Clinical trial activity remains robust, with 86 Phase III and 361 Phase II trials in the pipeline, setting the stage for continued commercial momentum as approvals materialize.
Executive Commentary
"Commercial therapy will be the driver of our future. I mean, it is the fastest-growing market... We're forecasting nine new therapies in 2026. And furthermore, we're forecasting 11 BLA, MAA filings to take place. So we're spring loaded for a brilliant future."
Gerald "Jerry" Shelton, Chief Executive Officer
"We improved just even about 12 million year over year. We are starting to invest in specific growth initiatives... That expected growth, together with some of the efficiencies that we've identified, will really drive the further margin improvement."
Robert Stavanovich, Chief Financial Officer
Strategic Positioning
1. Commercial Cell and Gene Therapy as Core Growth Engine
Cryoport’s future is tied to the scaling of commercial cell and gene therapies, now representing a structurally larger portion of revenue. Management’s focus on supporting new therapy launches and expanding commercial client relationships is central to its long-term trajectory.
2. Bioservices and Biostorage Expansion
Biostorage, the storage and management of biological samples, posted 22% growth, reflecting its critical role in supporting therapy development and commercialization. This segment is expected to accelerate further as more therapies receive approval.
3. Product Innovation and Digital Transformation
MVE Biological Solutions, the cryogenic systems arm, launched new products like the Fusion 800 freezer and integrated digital monitoring, expanding addressable markets and enhancing value proposition. Investments in AI and digital platforms are aimed at driving both operational efficiency and client stickiness.
4. Global Partnerships and Ecosystem Integration
Strategic alliances with DHL, Cardinal Health, and Parexel are designed to extend Cryoport’s reach and embed its solutions deeper into the cell and gene therapy ecosystem. While DHL integration will take time, these relationships are expected to drive standardization and industry adoption.
5. Margin and EBITDA Inflection
Operational discipline and cost initiatives have already improved margins, with the company targeting positive adjusted EBITDA in the back half of 2026. Strategic facility investments and process improvements are expected to further enhance profitability as revenue scales.
Key Considerations
Cryoport’s Q4 and full-year 2025 results underscore a business in transition, moving toward higher-value commercial revenue streams while maintaining operational rigor and strategic optionality.
Key Considerations:
- Pipeline Leverage: A record 760 clinical trials, with 86 in Phase III, positions Cryoport to benefit from upcoming therapy approvals and label expansions.
- Commercial Mix Shift: As commercial therapy revenue grows, the business model becomes less reliant on cyclical trial activity and more on recurring, durable contracts.
- Global Infrastructure Build-Out: New supply chain centers in Paris and California, as well as Belgian expansion, will support client growth and service differentiation.
- Digital and AI Investments: Early adoption of generative AI and cloud-based shipment management is intended to drive efficiency and accuracy, but execution risk remains.
- Strategic Partnership Ramp: While DHL and other alliances offer long-term upside, integration timelines are extended and benefits will be realized gradually.
Risks
Execution on commercial therapy launches and integration of new partnerships are pivotal risks. Macro volatility, regulatory delays, and slower-than-expected uptake of new therapies could dampen growth. While management expresses confidence in guidance, exposure to funding cycles and therapy approval timing remains a source of uncertainty. Margin gains depend on continued scale and operational discipline amid ongoing investment in infrastructure and digital transformation.
Forward Outlook
For Q1 2026, management indicated a solid start with no material disruptions expected from geopolitical events or flight cancellations.
- Full-year 2026 revenue guidance: $190 million to $194 million (high single-digit growth at the midpoint).
- Positive adjusted EBITDA targeted for the second half of 2026.
Management emphasized the following drivers for 2026:
- Anticipated nine new therapy approvals and 13 BLA/MAA filings, underpinning commercial revenue growth.
- Continued expansion of bioservices and commercial client base.
Takeaways
Cryoport’s business is pivoting decisively toward commercial cell and gene therapy support, with a robust pipeline and strategic partnerships setting the stage for multi-year growth and margin expansion.
- Commercial Therapy Growth: The company’s performance and pipeline position it to capitalize on the accelerating shift from clinical to commercial revenue streams.
- Operational Discipline: Margin improvement and EBITDA visibility are direct results of targeted cost initiatives and strategic investments in infrastructure.
- Future Watchpoint: Investors should monitor execution on new therapy launches, partnership integration, and the pace of bioservices adoption as indicators of sustained outperformance.
Conclusion
Cryoport’s Q4 2025 results highlight a business at an inflection point, with commercial cell and gene therapy revenue now the clear growth engine. Strategic partnerships, operational improvements, and a robust clinical pipeline reinforce the company’s leadership, but execution on upcoming launches and integration milestones will determine the trajectory in 2026 and beyond.
Industry Read-Through
Cryoport’s results and commentary underscore the accelerating maturation of the cell and gene therapy sector, as commercial approvals become a larger driver of supply chain demand. The company’s expansion of bioservices and digital capabilities signals that industry participants must build integrated, scalable platforms to capture the next wave of therapy launches. Strategic partnerships and ecosystem integration are becoming essential for differentiation, while operational discipline is increasingly rewarded as the sector moves toward profitability. Competitors and adjacent service providers should expect rising client expectations for end-to-end solutions, real-time monitoring, and global reach as the market standardizes and scales.